Colossal Biosciences

“Breaking plastic degradation company, Colossal spinout. Briefly mentioned alongside Form Bio and Astromech as the second spinout from Colossal's technology portfolio.”

“Viagen had cloning efficiencies at 80% where most people are at 2%. And so it made sense for us to say, okay, we need to buy them and bolt them on from a vertical integration perspective.”